follicle stimulating hormone

Phase 1Small molecule

follicle stimulating hormone is one of 77 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

GrowthActive, not recruiting

Metabolic SyndromePhase 1

Active, not recruiting

GrowthPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

Lovenox

Sanofi

Preclinical

2 3

Lenvima

Eisai

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Aricept

Eisai

Preclinical

1 6

Herceptin

OOrganon and Co

Preclinical

4 7

Somavaratan

Glucophage

2 9

EGRIFTA WR

TTheratechnologies

Preclinical

2 10

Neupogen

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Metabolic Syndrome

NCT06414096

Clinical

Trials by Indication[1]

Ovarian Stimulation2 trials

Efficacy of Ovarian Stimulation Based on FSHR Genotype Status

Suspended·MMedical University of Vienna·Phase 3·NCT00749853·165 enrolled

Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation

Completed·YYale University·Phase 3·NCT01044862·900 enrolled

Progesterone1 trial

Step Down FSH Approach and Late Follicular Phase in Progesterone Level

Completed·AART Fertility Clinics LLC·Phase 1·NCT03356964·127 enrolled

Growth1 trial

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF

Unknown status·CCenter for Human Reproduction·Phase 1/2·NCT02179255·30 enrolled

Metabolic Syndrome1 trial

Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome

Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT06414096·5 enrolled

Efficacy1 trial

Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.

Completed·IIBSA Institut Biochimique SA·Phase 3·NCT00335725·151 enrolled

2 more indications

Ovarian1 trial

Predicting Ovarian Response in Artificial Insemination With Low Stimulation

Unknown status·IIsala··NCT01662180·510 enrolled

Endothelial Function1 trial

Effects of FSH on Endothelial Function (FEND)

Unknown status·FFederico II University·Phase 4·NCT04430621·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for follicle stimulating hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — follicle stimulating hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for follicle stimulating hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IBSA Institut Biochimique SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IIBSA Institut Biochimique SA

follicle stimulating hormone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ovarian Stimulation2 trials

Progesterone1 trial

Growth1 trial

Metabolic Syndrome1 trial

Efficacy1 trial

Ovarian1 trial

Endothelial Function1 trial

References

Drug Info

Quick Facts

Related News